# Actin and focal adhesion remodeling as therapeutic targets in cardiovascular disease

> **NIH NIH R01** · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · 2020 · $529,157

## Abstract

Recent epidemiological studies have made clear that human proximal aortic stiffness increases with age and
is an early and independent biomarker of, and probable contributor to, subsequent adverse cardiovascular
outcomes including kidney failure, hypertension and Alzheimer's Disease-related dementia. The normal
flexibility of the proximal aorta functions as a critical “shock absorber” to protect small downstream vessels
from the high pulses of pressure generated by the heart. We have shown in published studies that the
vascular smooth muscle cell (VSMC) regulates up to half of total aortic stiffness and that aging-induced loss
of regulation of the VSMC cytoskeleton leads to impairment of the ability of the aorta to perform this shock
absorption function. A major advance from our lab has been the demonstration that the cortical nonmuscle
actin cytoskeleton and its linkages to focal adhesions and the extracellular matrix are a particularly dynamic
and important part of the VSMC cytoskeleton. The broad goal of this program is to test the concept that
ultrasound-targeted, cell permeant decoy peptides and small molecule inhibitors can be used both to probe
function and to reverse aging-induced malfunction of the VSMC cytoskeleton. We will use cell permeant
decoy peptides and recombinant proteins developed by our lab, and for comparison, small molecule
inhibitors, to test the hypothesis that ex vivo stiffness of aortas from aged mice can be decreased by
mechanisms targeted to the VSMC cytoskeleton. We will mine protein sequence data bases to identify
VSMC-specific sequences. Synthetic decoy constructs targeting these sequences will test a proof of concept
for the selectivity and efficacy of the peptide approach. We will use biomechanics, magnetic tweezers,
proximity ligation analysis, actin polymerization assays and immunoprecipitation to confirm the mechanism of
action of decoys. We will test, in collaboration with Tyrone Porter of our Nanoscience Center, the hypothesis
that microbubble-packaging of cell-permeant decoys and ultrasound-mediated release will allow localized,
tissue-specific targeted delivery of effective decoys. We will test the hypothesis that tissue-targeted decoys
can acutely reduce PWV in vivo in mice and that chronic in vivo treatment can prevent 3 negative outcomes
associated with aging-induced increased aortic stiffness: brain vascular lesions, hypertension and renal
damage. Hence, we propose a highly innovative research strategy to attack aging-induced alterations in the
vascular actin cytoskeleton and its linkage to focal adhesions. This approach, no matter the outcome, will
answer major questions about aortic stiffness and its relationship to vascular function with age. If successful,
this approach has the potential to prevent or reverse a host of aging-associated cardiovascular disorders.

## Key facts

- **NIH application ID:** 9932874
- **Project number:** 5R01AG053274-04
- **Recipient organization:** BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- **Principal Investigator:** KATHLEEN G MORGAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $529,157
- **Award type:** 5
- **Project period:** 2017-09-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9932874

## Citation

> US National Institutes of Health, RePORTER application 9932874, Actin and focal adhesion remodeling as therapeutic targets in cardiovascular disease (5R01AG053274-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9932874. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*